Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep : Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

08/31/2021 | 08:01am EDT

Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA31 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to advise its Chinese partner for eftilagimod alpha (“efti” or “IMP321”), EOC Pharma (“EOC”) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China.

EOC is preparing to initiate a clinical trial of efti in combination with an anti-PD-1 therapy. The new trial is expected to commence in the first half of calendar year 2022.

The new trial builds on the latest promising data presented by Immutep at ASCO 2021 and on EOC’s previously announced Phase II trial evaluating efti in combination with chemotherapy in metastatic breast cancer patients. This previously announced Phase II trial is currently expected to commence in the second half of calendar year 2021.

In addition, EOC has partnered with a contract development and manufacturing organisation in China. In August 2020, EOC received positive feedback from the Centre for Drug Evaluation (CDE), subordinate unit of China’s National Medical Products Administration (NMPA) on its CMC comparability study results and recently completed an important 2000L manufacturing step for efti.

Dr. Xiaoming Zou, CEO of EOC Pharma, commented: "Encouraged by our partner Immutep's exciting clinical performance, we are ready to further exploit the clinical benefits of this promising drug in the IO realm.”

Commenting on EOC’s plans, Immutep CEO Marc Voigt said: “It is great to see our growing confidence in efti is shared by our Chinese partner, EOC. Like Immutep, EOC is expanding its clinical trial pipeline, adding a new combination therapy study of efti with an anti-PD-1 drug. This is the same promising concept we are evaluating in TACTI-002 and TACTI-003, for example.”

Efti is exclusively licensed to EOC for the territory of Greater China. EOC has full responsibility for the development and commercialisation of efti in the territory, and Immutep is eligible to receive development-based milestone payments and sales-based royalties.

About EOC Pharma
EOC Pharma is an integrated biopharmaceutical company focusing on the discovery, research, development, and commercialisation of innovative oncology products. With an insight-driven strategic planning capability and highly integrated product platform, EOC Pharma strives to build a portfolio of products with synergies from independent R&D and partnering and enrich the product pipeline with first- and best-in-class oncology drugs to benefit the millions of patients who currently have limited access to high quality oncology treatments in China.

About Immutep

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by the Board of Immutep Limited.


Primary Logo

Source: Immutep Limited

2021 GlobeNewswire, Inc., source Press Releases

All news about IMMUTEP LIMITED
10/13IMMUTEP : Corporate Connect - A Truly Undervalued Company
PU
10/12IMMUTEP : 2021 Annual General Meeting and Key Dates
PU
10/04IMMUTEP : to Present Data, Trial Design of Clinical Studies for Cancer Treatments During M..
MT
10/03IMMUTEP : to present Phase II TACTI-002 data at SITC 2021
PU
10/01IMMUTEP : to Present Phase II TACTI-002 Data at SITC 2021
AQ
09/29IMMUTEP : Receives $2.49 Million as R&D Tax Incentive from French Government
MT
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government
AQ
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)
PU
09/28IMMUTEP : Receives $2.5 Million Tax Incentive from France
MT
09/28IMMUTEP : Receives A$3.4 million R&D French Tax Incentive
PU
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 2,38 M 1,78 M 1,78 M
Net income 2022 -38,7 M -28,9 M -28,9 M
Net cash 2022 82,0 M 61,3 M 61,3 M
P/E ratio 2022 -7,98x
Yield 2022 -
Capitalization 498 M 372 M 372 M
EV / Sales 2022 175x
EV / Sales 2023 22,9x
Nbr of Employees -
Free-Float 85,2%
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,59 AUD
Average target price 1,18 AUD
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
Frédéric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Co-Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED40.96%350
MODERNA, INC.220.51%135 157
LONZA GROUP AG27.29%58 232
IQVIA HOLDINGS INC.38.67%47 608
SEAGEN INC.-1.81%31 287
CELLTRION, INC.-39.28%24 952